Tradestie Institutional Equity Comparison Engine

XLO vs STLN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

XLO Overall Edge

XLO Captures Institutional Edge (3โ€“0 Pillars ยท 8โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Xilio Therapeutics, Inc. Common Stock (XLO) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, XLO trades at N/M Forward P/E with -74.9% operating margin (-47.6% YoY revenue) versus STLN at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, XLO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against STLN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner XLO
XLO N/M vs STLN N/M Fwd P/E
Growth & Margin Winner XLO
Op Margin -74.9% vs N/A ยท YoY -47.6% vs N/A
Momentum & Technical Winner XLO
1Y +836.8% vs -42.0% ยท 52W Pos 75% vs 1%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
XLO NASDAQ
Xilio Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$7.56
+0.67% 1D
Market Cap $53.1M
1M Return -5.85%
1Y Return +836.8%
Forward P/E N/M
Unified AI Score
45.8 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 50.0 Mom 74.0
STLN US Equity
STLN
Institutional Equity
$3.00
-5.66% 1D
Market Cap N/A
1M Return -56.58%
1Y Return -41.97%
Forward P/E N/M
Unified AI Score
46.6 / 100 HOLD
Tech 45.0 Fund 46.0 Flow 50.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: XLO +836.8% STLN -41.97% Spread: +25.14 pp (XLO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
XLO TTM Op. Margin: -74.9% STLN TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XLO vs STLN. Trailing 12-month operating profitability (XLO -74.9% vs STLN N/A) and valuation multiples (XLO N/M vs STLN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: XLO (8) vs STLN (1)
Institutional Metric XLO STLN Criterion Row Winner
Market Capitalization Scale $53.1M N/A Larger Scale XLO
Trailing P/E Ratio Valuation 11.6x N/M Lower Multiple XLO
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -47.6% N/A Higher Growth XLO
Operating Margin (TTM) Profitability -74.9% N/A Higher Margin XLO
Net Profit Margin Profitability -20.9% N/A Higher Margin XLO
Return on Equity (ROE) Capital Efficiency -38.2% N/A Higher ROE XLO
52-Week Range Position Momentum 75% ($0โ€“$10) 1% ($3โ€“$7) Stronger Trend XLO
Beta / 30D Volatility Risk Regime 0.74ฮฒ ยท 63% Vol 1.42ฮฒ ยท 175% Vol Lower Realized Risk XLO
Unified Institutional Score Composite Signal 45.8 / 100 (HOLD) 46.6 / 100 (HOLD) Higher Composite STLN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full XLO vs STLN Buy Guide
XLO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live XLO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
STLN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live STLN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither XLO nor STLN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.